OSE Immunotherapeutics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, OSE Immunotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of €14.07. The average 1-year stock price forecast is 314.56% higher than the current stock price, while the lowest is €8.20 (+141.60%) and the highest is €21.00 (+518.74%).

Price Target: €14.07 (+314.56%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	€8.20	€14.07	€13.00	€21.00
Change	+141.60%	+314.56%	+283.03%	+518.74%

* Price targets were last updated on Apr 30, 2026.

Analyst Ratings

The average analyst rating for OSE Immunotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Dec '25	Jan '26	Mar '26	May '26	Jun '26
Strong Buy	3	2	2	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	2	2	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Nicolas Pauillac Kepler Capital	Kepler Capital	Buy Maintains €8.20	Buy	Maintains	€8.20	+141.60%	Apr 30, 2026

Financial Forecast

Revenue This Year

6.25M

from 2.69M

132.26%

from 2.69M

Revenue Next Year

10.53M

from 6.25M

68.48%

from 6.25M

EPS This Year

-1.30

from -1.69

EPS Next Year

-1.13

from -1.30

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	26.31M	18.30M	2.23M	83.44M	2.69M	6.25M
Revenue Growth	152.48%	-30.43%	-87.83%	3,646.52%	-96.78%	132.26%
Operating Income	-16.63M	-18.48M	-22.99M	43.74M	-37.49M	-29.58M
Net Income	-16.85M	-17.76M	-23.00M	37.45M	-37.69M	-30.59M
EPS	-	-	-	-	-1.69	-1.30
Free Cash Flow	-4.21M	-9.07M	-11.18M	33.19M	-17.84M	-32.10M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	10.0M
Avg	6.3M
Low	2.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	271.6%
Avg	132.3%
Low	-7.1%

EPS Forecast

EPS	2026	2027	2028
High	-1.13
Avg	-1.30
Low	-1.60

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-